{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000093","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.333302+00:00","generated_at":"2026-05-19T06:16:19.663553+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cartesian Therapeutics stockholders elect three Class III directors and approve say-on-pay at 2025 annual meeting","bullets":["84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.","Non-binding advisory say-on-pay approved: 19.7M for, 157k against, 2.0M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025 approved: 21.8M for, 6k against."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000093","json":"https://secwatch.observer/filing/0001453687-25-000093.json","markdown":"https://secwatch.observer/filing/0001453687-25-000093.md","text":"https://secwatch.observer/filing/0001453687-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000093/0001453687-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000093/rnac-20250613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:16:19.663553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}